International Conference on the Management of Patients with Viral Hepatitis

Organised by Pr Patrick Marcellin

Organising Committee: Tarik Asselah, Nathalie Boyer, Michelle Martinot

Hôpital Beaujon, APHP
 Université Paris - Diderot
 INSERM CRB3

17 & 18 January 2011
 PARIS - Palais des Congrès

www.aphc.info
Dear colleagues,

The fourth Paris Hepatitis Conference (PHC) provides the state of the art on the management of patients with hepatitis B and hepatitis C in 2011. Once again, this year, outstanding international experts will be presenting reviews of the most up-to-date information as well as their opinion on its clinical applications.

Since the last meeting, historical milestones have been achieved in chronic hepatitis B. Long-term follow-up of patients receiving the most potent available antivirals has shown high sustained virological response with no or very little resistance. The quantification of HBsAg has emerged recently as a potential new tool for predicting outcome.

Spectacular steps forward were made in chronic hepatitis C with the first genetic predictor of response and the results of phase 3 studies of triple therapy with protease inhibitors, telaprevir or boceprevir. Thus, triple therapy will undoubtedly become the new standard of care in the next couple of years in patients infected with HCV genotype 1.

The aim of this 4th PHC is to provide clinicians with the state of the art and its clinical applications to optimise the management of patients with hepatitis B and hepatitis C. Indeed our ultimate goal is to provide optimal therapy and the best chance of cure to as many patients as possible, worldwide.

I wish you a most pleasant stay in Paris and a very fruitful meeting.

Best wishes,

Patrick Marcellin
8:45 Introduction: Viral hepatitis in 2011  
Patrick Marcellin (France)

8:55 -10:45 Chairpersons: Nezam Afdhal (USA), Massimo Levreto (Italy)
Hepatitis C: towards a personalised management

8:55  ■ Optimal use of virological tools  Stefan Zeuzem (Germany)
9:15  ■ Genetic markers: a major step for individualised care  John McHutchison (USA)
9:35  ■ Impact of SVR on the long term outcome  Alfredo Alberti (Italy)
9:55  ■ Serum markers or elastometry vs liver biopsy?  Laurent castera vs Pierre Bedossa (France)

10:15  ■ Round table

10:30 - 11:00  ■ Coffee Break

11:00 -12:30 Chairpersons: Peter Ferenci (Austria), Jake Liang (USA)
Optimising therapy in real life

11:00  ■ The role of triple therapy in genotype 1:  
David Nelson (USA)
- Naive patients
- Experienced patients
11:30  ■ Optimal therapy in non-1 genotypes:  
Antonio Craxi (Italy)
- genotype 2 and 3 patients
- genotype 4 patients
12:00  ■ Round table

12:30 -14:00
Interactive luncheons (details on central page)

14:00 -15:45 Chairpersons: Marc Boullière (France), Michael Manns (Germany)
The future

14:00  ■ New combinations  
Tarik Asselah (France)
- Advantages of new generation DAAs?
- Is ribavirin still useful?
- Are interferons really necessary?
14:45  ■ Round table
15:15  ■ Clinical case: management of a non responder  
Eugene Schiff (USA)

15:45 - 16:15  ■ Coffee Break

16:15 -17:45 Chairpersons: Masao Omata (Japan), Dominique Valla (France)
Management of Hepatocellular Carcinoma

16:15  ■ Liver transplantation: expanding criteria?  
Jacques Belghiti (France)
16:30  ■ Local regional approach  
Josep Llovet (Spain)
16:45  ■ Novel molecular therapy  
Eric Raymond (France)
17:00  ■ How I manage my patients with hepatocellular carcinoma  
Massimo Colombo (Italy)
17:15  ■ The Zurich HCC liver transplantation consensus conference  
Pierre-A. Clavien (Switzerland)
17:30  ■ Round table

18:00 -18:30 Chairman: Patrick Marcellin (France)
■ Milestones and perspectives in hepatitis B  
Award ceremony  
Stephanos Hadziyannis (Greece)

20:00 Congress Dinner
HEPATITIS C
Monday January 17, 2011 • 12:30 - 14:00

Room 241 - Level 2
1. Non invasive markers of fibrosis: an easy access to treatment?
   Chair: Nezam Afzhal (USA)
   Speakers: Victor de Ledhingen (France), Anna Carolina Cardoso (Brazil)

Room 242A - Level 2
2. Individualised approach to managing naive patients
   Chair: Alfredo Alberti (Italy)
   Speakers: Gamal Esmat (Egypt), Philippe Mathurin (France)

Room 242B - Level 2
3. Triple therapy: who and how?
   Chair: Stephan Zeuzem (Germany)
   Speakers: Christophe Hezode (France), Robert Flisiak (Poland)

Room 243 - Level 2
4. Management of difficult to treat patients
   Chair: Antonio Crazzi (Italy)
   Speakers: Jean-Pierre Bronowicki (France), Marina Berenguer (Spain)

Concorde Room A - Level 4
5. French speaking luncheon: Comment prendre en charge les patients atteints d’hépatite C ?
   Chair: Daniel Dhumeaux (France)
   Speakers: Patrice Couzigou (France), Najet Bel Hadj Brik (Tunisie)

HEPATITIS B
Tuesday January 18, 2011 • 12:30 - 14:00

Room 241 - Level 2
1. The role of HBsAg quantification vs HBV DNA in clinical management of Hepatitis B
   Chair: Sam Lee (Canada)
   Speakers: Maurizia Brunetto (Italy), Teerha Piratvisuth (Thailand)

Room 242A - Level 2
2. Hepatocellular carcinoma. Asian vs European experience
   Chair: Massimo Colombo (Italy)
   Speakers: Pierre-Alain Clavien (Switzerland), Masao Omata (Japan)

Room 242B - Level 2
3. How to manage patients with resistant HBV
   Chair: Marion Peters (USA)
   Speakers: Maria Buti (Spain), Lawrence Serfaty (France)

Room 243 - Level 2
4. Active or inactive carrier: where is the frontier?
   Chair: Thomas Berg (Germany)
   Speakers: Jean-Pierre Zarski (France), Nancy Leung (China)

Concorde Room - Level 4
5. French speaking luncheon: Comment optimiser la prise en charge des patients AgHBe négatif?
   Chair: Christian Trepo (France)
   Speakers: Mihai Voiculescu (Romania), Mustapha Benazzouz (Morroco)
HEPATITIS B - Amphitheatre Bleu

8:30 - 10:00 Chairpersons: Raphael Esteban (Spain) and Shiv Kumar Sarin (India)

Hepatitis B: towards a personalised management

8:30  ■ Impact of therapy on the long term outcome of liver disease  Yun-Fan Liaw (Taiwan)
8:45  ■ Is resistance disappearing?  Fabien Zoulim (France)
9:00  ■ HBsAg: virologic significance  Maurizia Brunetto (Italy)
9:15  ■ HBsAg: clinical relevance  Rami Moucari (France)
9:30  ■ Round table

☕ 10:00 - 10:30  ■ Coffee Break

10:30 - 11:30 Chairpersons: Sam Lee (Canada) and Ji-Dong Jia (China)

HBeAg-positive chronic hepatitis B

10:30  ■ Why do I treat my patient with a nucleos(t)ide analogue?  Nancy Leung (Hong Kong)
10:50  ■ Why do I treat my patient with pegylated interferon?  Harry Janssen (The Netherlands)
11:10  ■ Round table

11:30 - 12:30 Chairpersons: Geoffrey Dusheiko (UK) and Feruccio Bonino (Italy)

HBeAg-negative chronic hepatitis B

11:30  ■ Why do I treat my patient with a nucleos(t)ide analogue?  George Papatheodoridis (Greece)
11:50  ■ Why do I treat my patient with pegylated interferon?  Pietro Lampertico (Italy)
12:10  ■ Round table

12:30 - 14:00 Interactive luncheons (details on central page)

14:00 - 14:30

Clinical case: cirrhosis with lamivudine resistance  Marion Peters (USA)

14:30 - 15:30 Chairpersons: Cihan Yurdaydin (Turkey) and Mario Rizzetto (Italy)

Special populations

14:30  ■ HIV co-infection: does it make a difference?  Stanislas Pol (France)
14:50  ■ Difficulties faced in severe reactivation  Didier Samuel (France)
15:10  ■ Hepatitis delta revival  Heiner Wedemeyer (Germany)

15:30 - 16:00 Chairman: Tarik Asselah (France)

State of the Art lecture

■ Metabolic syndrome and HCV: from theory to clinical practice  Arun Sanyal (USA)

Conclusion and perspectives  Patrick Marcellin (France)
CONFERENCES DATES AND VENUE
From Monday, 17 January 2011
To Tuesday, 18 January 2011
At the Palais des Congrès
1 place Maillot - 75017 Paris

CONFERENCE REGISTRATION DESK
17 & 18 January, from 7:00 am.
Welcome desks are organized on level 2 of the Palais des Congrès in Foyer Bleu next to the Amphitheatre Bleu. You will be able to register on site, retrieve your access badge, congress bag and proceedings.

CONGRESS OFFICE
During the Congress
Welcome Desk
Tel.: +33 (0) 1 40 68 27 08
After the Congress
Colloquium/ PHC 2011
Congress Administrative Secretariat
12 rue de la Croix-Faubin
75011 Paris – France
Tel.: +33 (0) 1 44 64 15 15
Fax: +33 (0) 1 44 64 15 16
phc2011@clq-group.com
www.phc.info

CONGRESS HOTELS
Concorde Lafayette Hotel
3 place du Général Koenig
75017 Paris
Tel: + 33 (0) 1 40 68 50 68
Intercontinental Paris Le Grand
2 rue Scribe
75442 Paris
Tel.: +33 (0) 1 40 07 32 32
Méridien Etoile Hotel
81 boulevard Gouvion St-Cyr
75 017 Paris
Tel: +33 (0) 1 40 68 34 34

CONGRESS DINNER
Monday, 17 January at the Intercontinental Paris Le Grand, in the named lounge “Opéra”. 7:30 pm: buses departure from the official hotels.
Dress code: cocktail attire

CONTINUING MEDICAL EDUCATION (CME)
The “APHC” is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS): www.uems.net.
The 4th Paris Hepatitis Conference is designated for a maximum of (or “for up to”) 11 hours of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

LIVER INTERNATIONAL
The PHC Liver International supplement is available online at the following address: http://blackwellpublishing.com

LUNCHES
2 types of lunches are organized each day:
- Working Luncheons (Level 2).
  The number of seats is limited, an invitation card will be requested on entrance. Ask the welcome desk for registration, according to the luncheons sessions program.
- Regular luncheons are organized in Salons Concorde (Level 4).

METRO and RER
The metro station (line 1) and RER station (line C) are located on level -1 of the Palais des Congrès: Porte Maillot station.
The Conference will be held in Amphitheatre Bleu on level 2.

OFFICIAL LANGUAGE
The official language of the conference is English.

GENERAL INFORMATION